OLMA — Olema Pharmaceuticals, Inc. stock price, charts and financials

Latest market price

11.96

-0.09-0.71%

Overview Short InterestFilings

OLMAQT70Olema Pharmaceuticals, Inc.·NASDAQ

Overview Short InterestFilings

11.96-0.71%

Earnings

Down 0.7% — Reported earnings — EPS beat by 2%.

High confidence

Loading chart...

Signal & projected range

Short-squeeze setupHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

AUPH-2.33%$15.48 MESO+4.23%$16.61 ZBIO-0.58%$32.24 GHRS-1.72%$29.75 TSHA-1.45%$6.46 STOK-1.44%$32.24 ABCL+36.08%$9.43 VRDN-2.67%$22.96

Snapshot

Index	-	P/E	-	EPS (ttm)	-	Insider Own	41.23%	Shs Outstand	87.35M	Perf Week	5.24%

Market Cap	1.05B	Forward P/E	-	EPS next Y	-2.40	Insider Trans	-0.18%	Shs Float	70.84M	Perf Month	-1.87%

Enterprise Value	1.00B	PEG	-	EPS next Q	-	Inst Own	-	Short Float	21.32%	Perf Quarter	-20.36%

Income	-157.35M	P/S	0.00	EPS this Y	-	Inst Trans	-	Short Ratio	10.66	Perf Half Y	-51.82%

Sales	0.00	P/B	2.58	EPS next Y	-8.51%	ROA	-34.89%	Short Interest	15.10M	Perf YTD	-51.80%

Book/sh	-	P/C	-	EPS next 5Y	-	ROE	-45.95%	52W High	36.01 -66.77%	Perf Year	141.97%

Cash/sh	-	P/FCF	-	EPS past 3/5Y	-	ROIC	-41.66%	52W Low	4.44 169.57%	Perf 3Y	23.97%

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-	Gross Margin	0.00%	Volatility	5.34% 5.50%	Perf 5Y	-48.68%

Dividend TTM	-	EV/Sales	0.00	EPS Y/Y TTM	8.18%	Oper. Margin	0.00%	ATR (14)	0.67	Perf 10Y	-

Dividend Ex-Date	-	Quick Ratio	10.88	Sales Y/Y TTM	-	Profit Margin	0.00%	RSI (14)	54.68	Recom	2.00

Dividend Gr. 3/5Y	-	Current Ratio	10.88	EPS Q/Q	-44.44%	SMA20	3.66%	Beta	1.95	Target Price	40.33

Payout	0.00%	Debt/Eq	0.00	Sales Q/Q	-	SMA50	6.26%	Rel Volume	0.53	Prev Close	12.05

Employees	131	LT Debt/Eq	0.00	Earnings	Aug 10	SMA200	-31.16%	Avg Volume	1.43M	Price	11.96

IPO Date	Nov 19, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	2.02% -	Net Debt/EBITDA	0.28	Volume	757,195	Change	-0.71%

Analyst Ratings

Date	Action	Analyst	Rating	Target
May-13-26	Reiterated	Guggenheim	Buy	$40 → $35
Mar-09-26	Reiterated	HC Wainwright & Co.	Buy	$45 → $38
Feb-10-26	Initiated	Stifel	Buy	$48
Jan-07-26	Initiated	Piper Sandler	Overweight	$40
Jan-07-26	Reiterated	UBS		$45
Dec-11-25	Reiterated	Goldman Sachs	Buy	$26 → $38
Dec-11-25	Reiterated	HC Wainwright & Co.	Buy	$36 → $45
Dec-11-25	Reiterated	Oppenheimer	Outperform	$48
Dec-10-25	Reiterated	Jefferies		$30 → $43
Nov-21-25	Reiterated	Goldman Sachs	Buy	$27 → $26

Latest News

Aug-04-26

Aug-04-2604:30PM

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com

Jul-27-26

Jul-27-2605:06PM

12 Health Care Stocks Moving In Monday's After-Market SessionBenzinga

Jun-30-26

Jun-30-2609:00PM

Wondering what's happening in today's after-hours session?ChartMill

Company

Olema Pharmaceuticals, Inc., a biopharmaceutical enterprise in the clinical development stage, is dedicated to discovering, advancing, and commercializing therapeutic solutions for women's oncology. Headquartered in San Francisco, California, the company was established in 2006 and rebranded from CombiThera, Inc. in March 2009. Its most promising investigational compound, OP-1250, an estrogen receptor (ER) antagonist and selective ER degrader, is presently undergoing Phase 1/2 clinical evaluations. This drug candidate is being assessed for its efficacy in managing recurrent, locally advanced, or metastatic breast cancer that expresses estrogen receptors but is negative for human epidermal growth factor receptor 2.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	0	0	0	—	—	—	—	—
Cost of Goods Sold Incl. D&A	0	0	0	—	—	—	—	—
Gross Profit	0	0	0	—	—	—	—	—
Selling, General and Administrative Excl. Other	21	18	19	—	—	—	—	—
Research and Development	158	125	86	—	—	—	—	—
Other Operating Expense	0	-1	0	—	—	—	—	—
Operating Income	-179	-142	-105	—	—	—	—	—
Interest Expense	0	0	0	—	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	16	13	8	—	—	—	—	—
Net Income Before Taxes	-162	-129	-97	—	—	—	—	—
Income Taxes	0	0	0	—	—	—	—	—
Consolidated Net Income	-162	-129	-97	—	—	—	—	—
Net Income From Continuing Operations	-162	-129	-97	—	—	—	—	—
Net Income	-162	-129	-97	—	—	—	—	—
EPS (Recurring)	-1.87	-2.20	-2.14	—	—	—	—	—
EPS (Basic, Before Extraordinaries)	-1.87	-2.20	-2.14	—	—	—	—	—
EPS (Diluted)	-1.87	-2.20	-2.14	—	—	—	—	—
EBITDA	-162	-129	-96	—	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	—	—
Price To Sales Ratio	—	—	—	—	—	—	—	—
Gross Margin	—	—	—	—	—	—	—	—
Operating Margin	—	—	—	—	—	—	—	—
Net Margin	—	—	—	—	—	—	—	—
Shares Outstanding	87	59	45	—	—	—	—	—
Market Capitalization	2,175	344	631	—	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Harmon Cyrus	Director	Jul 24 '26	Sale	11.71	12,500	146,425	702,770	Jul 27
Harmon Cyrus	Director	Jul 23 '26	Sale	11.58	12,500	144,738	715,270	Jul 27
Mitchell Shawnte	CHIEF LEGAL OFFICER	Mar 04 '26	Sale	24.25	25,000	606,353	0	Mar 05
Mitchell Shawnte	CHIEF LEGAL OFFICER	Mar 04 '26	Option Exercise	4.37	25,000	109,250	25,000	Mar 05
Mitchell Shawnte	CHIEF LEGAL OFFICER	Mar 03 '26	Sale	23.01	15,000	345,150	0	Mar 05
Mitchell Shawnte	CHIEF LEGAL OFFICER	Mar 03 '26	Option Exercise	4.37	15,000	65,550	15,000	Mar 05
Harmon Cyrus	Director	Jan 20 '26	Sale	26.88	10,000	268,800	727,770	Jan 21
Harmon Cyrus	Director	Jan 14 '26	Sale	29.12	3,489	101,600	737,770	Jan 16
Kovacs Shane William Charles	CH. OPERATING & FINANCIAL OFF.	Jan 15 '26	Sale	28.73	100,000	2,873,000	139,727	Jan 15
Kovacs Shane William Charles	CH. OPERATING & FINANCIAL OFF.	Jan 13 '26	Sale	28.01	3,822	107,054	239,727	Jan 15
Myles David C.	CH. DISCOV. & NON-CLIN DEV OFF	Jan 14 '26	Sale	28.87	50,000	1,443,651	542,761	Jan 14
Myles David C.	CH. DISCOV. & NON-CLIN DEV OFF	Jan 14 '26	Option Exercise	4.87	50,000	243,500	592,761	Jan 14
Myles David C.	CH. DISCOV. & NON-CLIN DEV OFF	Jan 13 '26	Sale	27.60	50,000	1,380,178	542,761	Jan 14
Myles David C.	CH. DISCOV. & NON-CLIN DEV OFF	Jan 13 '26	Option Exercise	4.87	50,000	243,500	100,000	Jan 14
Myles David C.	CH. DISCOV. & NON-CLIN DEV OFF	Jan 12 '26	Sale	28.34	10,000	283,400	144,846	Jan 14

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.